These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9054420)

  • 1. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry.
    Fantini J; Hammache D; Delézay O; Yahi N; André-Barrès C; Rico-Lattes I; Lattes A
    J Biol Chem; 1997 Mar; 272(11):7245-52. PubMed ID: 9054420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells.
    Yahi N; Sabatier JM; Nickel P; Mabrouk K; Gonzalez-Scarano F; Fantini J
    J Biol Chem; 1994 Sep; 269(39):24349-53. PubMed ID: 7929093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.
    Yahi N; Sabatier JM; Baghdiguian S; Gonzalez-Scarano F; Fantini J
    J Virol; 1995 Jan; 69(1):320-5. PubMed ID: 7983725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of single- and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activity.
    Faroux-Corlay B; Clary L; Gadras C; Hammache D; Greiner J; Santaella C; Aubertin AM; Vierling P; Fantini J
    Carbohydr Res; 2000 Jul; 327(3):223-60. PubMed ID: 10945673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of human immunodeficiency virus type I (HIV-1) gp120 to galactosylceramide (GalCer): relationship to the V3 loop.
    Cook DG; Fantini J; Spitalnik SL; Gonzalez-Scarano F
    Virology; 1994 Jun; 201(2):206-14. PubMed ID: 8184533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
    Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
    Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
    Delézay O; Hammache D; Fantini J; Yahi N
    Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry.
    Garg H; Francella N; Tony KA; Augustine LA; Barchi JJ; Fantini J; Puri A; Mootoo DR; Blumenthal R
    Antiviral Res; 2008 Oct; 80(1):54-61. PubMed ID: 18538869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4.
    Benjouad A; Chapuis F; Fenouillet E; Gluckman JC
    Virology; 1995 Jan; 206(1):457-64. PubMed ID: 7831801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3.
    Hammache D; Piéroni G; Yahi N; Delézay O; Koch N; Lafont H; Tamalet C; Fantini J
    J Biol Chem; 1998 Apr; 273(14):7967-71. PubMed ID: 9525894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β-galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop.
    Andrianov AM; Kornoushenko YV; Kashyn IA; Kisel MA; Tuzikov AV
    J Biomol Struct Dyn; 2015; 33(5):1051-66. PubMed ID: 24942968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.
    Nehete PN; Vela EM; Hossain MM; Sarkar AK; Yahi N; Fantini J; Sastry KJ
    Antiviral Res; 2002 Dec; 56(3):233-51. PubMed ID: 12406507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of anti-HIV activity of succinylated human serum albumin.
    Kuipers ME; vd Berg M; Swart PJ; Laman JD; Meijer DK; Koppelman MH; Huisman H
    Biochem Pharmacol; 1999 Apr; 57(8):889-98. PubMed ID: 10086322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection.
    Zanotto C; Calderazzo F; Dettin M; Di Bello C; Autiero M; Guardiola J; Chieco-Bianchi L; De Rossi A
    Virology; 1995 Feb; 206(2):807-16. PubMed ID: 7856094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides.
    Batinić D; Robey FA
    J Biol Chem; 1992 Apr; 267(10):6664-71. PubMed ID: 1551875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
    Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
    J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Density dependent interaction of polymeric analogs of beta-galactosyl ceramide with GP120 of human immunodeficiency virus 1.
    Fujita E; Nishimura SI
    Carbohydr Lett; 2000; 4(1):53-60. PubMed ID: 11469338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line.
    Harouse JM; Collman RG; González-Scarano F
    J Virol; 1995 Dec; 69(12):7383-90. PubMed ID: 7494242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of V3 loop-binding proteins as potential receptors implicated in the binding of HIV particles to CD4(+) cells.
    Callebaut C; Blanco J; Benkirane N; Krust B; Jacotot E; Guichard G; Seddiki N; Svab J; Dam E; Muller S; Briand JP; Hovanessian AG
    J Biol Chem; 1998 Aug; 273(34):21988-97. PubMed ID: 9705340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfatide inhibits HIV-1 entry into CD4-/CXCR4+ cells.
    Fantini J; Hammache D; Delézay O; Piéroni G; Tamalet C; Yahi N
    Virology; 1998 Jul; 246(2):211-20. PubMed ID: 9657940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.